Boris Sepesi - Concepedia

Author

Boris Sepesi

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

B Sepesi, B. Sepesi, Boris Sepesi, J.Jack Lee, Jianjun Zhang, Mara B. Antonoff, Paul Scheet, Yasir Elamin

470

Publications

12.7K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Baylor College of Medicine University of Colorado Denver University of Rochester

About

Boris Sepesi is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	83	5.8K
2	Health Sciences	14	17	1.5K
3	Engineering	2	2	48
4	Nursing	1	1	20
5	Anesthesia	1	1	15

Boris Sepesi

149

Publications

11.6K

Citations

H-Index

Page 1

	Year	Citations
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study Daniel R. Gomez, Chad Tang, Jianjun Zhang, Journal of Clinical Oncology	2019	1.2K
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study Daniel R. Gomez, George R. Blumenschein, J. Jack Lee, The Lancet Oncology First-line Systemic TherapyMedicineCancer ManagementBronchial NeoplasmCombined Modality Treatment	2016	1.1K
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial Tina Cascone, William N. William, Annikka Weissferdt, Nature Medicine Neostar TrialMedicineImmune Checkpoint InhibitorCancer TreatmentPhase 2	2021	582
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma Sangeeta Goswami, Thomas Walle, Andrew Cornish, Nature Medicine Neuro-oncologyCancer ImmunosurveillanceGliomaCombinatorial TargetImmunology	2019	368
Perioperative Nivolumab in Resectable Lung Cancer Tina Cascone, Mark M. Awad, Jonathan Spicer, New England Journal of Medicine	2024	356
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery Joe Y. Chang, Reza J. Mehran, Lei Feng, The Lancet Oncology Surgical OncologyRadiation TherapyMedicineBronchial NeoplasmThoracic Surgery	2021	304
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) Julie R. Brahmer, Ramaswamy Govindan, Robert A. Anders, Journal for ImmunoTherapy of Cancer ImmunologyPathologyMetronomic ChemotherapyImmunotherapyTumor Biology	2018	243
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence Alexandre Reuben, Rachel M. Gittelman, Jianjun Gao, Cancer Discovery	2017	232
Comprehensive T cell repertoire characterization of non-small cell lung cancer Alexandre Reuben, Jiexin Zhang, Shin-Heng Chiou, Nature Communications	2020	221
Enhanced Recovery Decreases Pulmonary and Cardiac Complications After Thoracotomy for Lung Cancer Robert M. Van Haren, Reza J. Mehran, Gabriel E. Mena, The Annals of Thoracic Surgery Lung TransplantationCardiac ComplicationsMedicineBronchial NeoplasmThoracic Surgery	2018	193

Page 1